The UK and US have established a major bilateral deal that will preserve no levies on UK pharmaceutical products going into the American market.
The Terms of the Accord
As part of the deal, the UK has pledged to raise spending on medicines through the NHS. This move secures that tariffs on these crucial goods will remain at nothing for a duration of three years.
This development comes after previous threats to hike duties on branded drug products, with potential rates mentioned reaching 100%.
"This arrangement between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue balance to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Importance
Drugs represent one of the Britain's largest exports to the United States, which is by far the biggest market for large British pharmaceutical firms.
Export figures indicate that in the year leading up to last September, the UK shipped pharmaceutical products totaling billions to the US. This figure made up 17.4% of British export trade in that timeframe.
"This agreement secures employment, stimulates capital expenditure and paves the way for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary commented.
Key British Pledges
The deal includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to increase total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds topped 20%.
Broader Context
The deal follows a long-running tension between the sector and the ministers over drug pricing and regulatory access.
The disagreement were exacerbated by arguments that US customers were charged several times more for the same drugs than patients in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been halted or abandoned, while major investments have been directed toward US facilities.
The Science Minister stated that the NHS had to invest a greater share on treatments, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.
